| Size | Price | |
|---|---|---|
| 250mg | ||
| Other Sizes |
| Targets |
Resorcinol monoacetate does not have a specific biological target but exhibits antibacterial activity. It increases collagen crosslinking and prevents bacterial growth on surfaces. The compound's mechanism of action may involve disruption of bacterial cell membranes or interference with cellular processes. Its keratolytic and antiseborrheic properties are related to its phenolic structure.
|
|---|---|
| ln Vitro |
In vitro, resorcinol monoacetate exhibits antibacterial activity, preventing the growth of bacteria such as Bacillus subtilis on sponge surfaces when attached to collagen sponges at 2% or 5% (w/w). It also increases collagen crosslinking. The compound is used as a preservative and disinfectant in various applications. Its keratolytic properties make it useful for skin care formulations.
|
| ln Vivo |
In vivo, resorcinol monoacetate is used as a pharmaceutical intermediate and functional ingredient in topical formulations. It has potential for research into acne, hyperkeratosis, and scalp conditions. The compound's keratolytic and antiseborrheic properties are based on its traditional use in dermatology. However, detailed in vivo pharmacological studies are limited.
|
| Enzyme Assay |
For in vitro antibacterial assays, resorcinol monoacetate is tested against bacterial strains such as Bacillus subtilis. Bacteria are cultured in appropriate media and incubated with varying concentrations of the compound (typically 0.1-10% w/w). The minimum inhibitory concentration (MIC) is determined by broth microdilution or agar diffusion methods. Bacterial growth inhibition is assessed by measuring optical density or colony count.
|
| Cell Assay |
For in vitro cell-based assays, resorcinol monoacetate is typically tested on keratinocytes or fibroblasts to evaluate its effects on skin cells. Cells are treated with the compound at various concentrations (typically 1-100 µM) for 24-48 hours. Cell viability is assessed using MTT assays. Collagen crosslinking can be measured using biochemical assays. Inflammatory cytokine production can be measured by ELISA.
|
| Animal Protocol |
For in vivo animal experiments, resorcinol monoacetate is typically applied topically to the skin of rodents. The compound is formulated in a suitable vehicle and applied at doses of 1-10% for 1-4 weeks. Skin thickness, erythema, and histopathological changes are assessed. The compound's keratolytic and anti-acne effects can be evaluated in models of hyperkeratosis or acne.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for resorcinol monoacetate are limited. As a small molecule with a molecular weight of 152.15 g/mol and formula C₈H₈O₃, it is expected to be absorbed through the skin when applied topically. It is hydrolyzed to resorcinol and acetic acid. Resorcinol is metabolized in the liver and excreted in urine. The compound's systemic exposure is likely limited with topical application.
|
| Toxicity/Toxicokinetics |
Toxicological data for resorcinol monoacetate indicate that it may cause skin irritation at high concentrations. Resorcinol, its hydrolysis product, has been associated with thyroid effects and methemoglobinemia at high systemic doses. The compound is classified as a research-grade reagent and is not for human therapeutic use. Standard laboratory safety practices should be followed when handling.
|
| Additional Infomation |
Resorcinol monoacetate is a derivative of resorcinol compounds, in which one phenolic hydroxyl group is converted to an acetate ester. It has keratolytic properties and was once used to treat acne. It can also be used as an antibacterial agent and in dermatological medicine. It belongs to the phenolic and phenylacetic acid ester classes and is functionally related to resorcinol.
See also: Resorcinol (note moved to). Resorcinol monoacetate is a research-use only compound and has not been approved for clinical applications. It is also known as 3-hydroxyphenyl acetate and acetylresorcinol. Its molecular weight is 152.15, and its formula is C₈H₈O₃. The compound is available from various research chemical suppliers for pharmaceutical and cosmetic research. |
| Molecular Formula |
C8H8O3
|
|---|---|
| Molecular Weight |
152.1473
|
| Exact Mass |
152.047
|
| CAS # |
102-29-4
|
| PubChem CID |
5055
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.223 g/mL at 25 °C(lit.)
|
| Boiling Point |
283 °C(lit.)
|
| Melting Point |
129-133 °C
|
| Flash Point |
>230 °F
|
| Vapour Pressure |
1.81E-05mmHg at 25°C
|
| Index of Refraction |
n20/D 1.537(lit.)
|
| LogP |
1.317
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
144
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])([H])[H])=O)C1=C([H])C([H])=C([H])C(=C1[H])O[H]
|
| InChi Key |
ZZPKZRHERLGEKA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H8O3/c1-6(9)11-8-4-2-3-7(10)5-8/h2-5,10H,1H3
|
| Chemical Name |
(3-hydroxyphenyl) acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 43 mg/mL (~282.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (13.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (13.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5725 mL | 32.8623 mL | 65.7246 mL | |
| 5 mM | 1.3145 mL | 6.5725 mL | 13.1449 mL | |
| 10 mM | 0.6572 mL | 3.2862 mL | 6.5725 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
